Clinical Trial Update: Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer [Phase 3]

View source ↗

Summary

Phase III trial evaluating DP (docetaxel + cisplatin) followed by FOLFIRI versus the reverse sequence in unresectable gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Samsung Medical Center | Conditions: Gastric Cancer, Metastases | Phase 3 | Status: COMPLETED